Efflux inhibitors: A strategy to tackle multidrug resistance

Progressing a discovery project – Criteria and challenges

Difficult-to-treat resistance (DTR)

What does the future look like if pull incentives to support antibiotic R&D are insufficient?

SECURE: Improving access to antibiotics through new economic models

What do the various non-commercial actors in the antibiotic R&D ecosystem do?

Putting public health needs at the centre of antibiotic drug development

Endpoints for antibacterial trials: microbiologic

Endpoints for antibacterial trials: timing of assessments

GARDP: An innovative public health approach to counter AMR

GARDP - Celebrating 5 years

Exploring opportunities to improve the treatment of gonorrhoea in Thailand

Staying one step ahead of the bug

The fight against drug resistant gonorrhoea

Lead optimization

Market interventions to improve access to antibiotics for resistant infections

Research brings hope for better antibiotic treatment for babies

Antibiotic shortages causes, consequences, and solutions

Clinical trial platforms for new and neglected antimicrobials

Starting an antibacterial drug discovery screening programme

Antimicrobial drug discovery: SAR optimization and QSAR

Lifesaving treatment for neonatal sepsis in Uganda

Adverse event / Serious Adverse event

Project management in antimicrobial drug R&D

Confronting the growing threat of antibiotic resistance - 76th World Health Assembly

Life is on the line #PowerOfAntibiotics

How can non profit drug developers counter AMR?

Promise of artificial intelligence to antibacterial drug discovery

Susceptibility testing in antibacterial drug R&D

Delivery systems in antibacterial drug discovery